Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 ...

Katt et al, The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma, ...

Holmen and her research team found that inhibiting the enzyme FAK in combination with an inhibitor of RAF and MEK—which targets ... in the first place." The oral treatment combines two drugs ...

inhibitor and avutometinib, an oral RAF/MEK clamp, and defactinib, an oral FAK inhibitor. "At this year’s AACR annual meeting, we show that VS-7375, our oral KRAS G12D (ON/OFF) inhibitor ...

The availability of MEK inhibitor drugs such as selumetinib ... we must be sure that the patient will be compliant with treatment and understand that these oral medications have potential side effects ...

The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most ...

QTX3544 is an oral, G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor currently being evaluated in a Phase 1 clinical trial in patients with KRASG12V mutations. The mitogen-activated ...